{"url_path":"/sec/imux/8-k/2026-06-29/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-29","source_url":"https://www.sec.gov/Archives/edgar/data/1280776/0001193805-26-000882-index.html","accession_number":"0001193805-26-000882","cik":"0001280776","ticker":"IMUX","issuer_name":"IMMUNIC, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1280776/0001193805-26-000882-index.html","primary_entity_key":"0001280776","primary_entity_name":"IMMUNIC, INC."},"word_count":171,"has_tables":true,"body_markdown":"**Item 5.02. Departure of Directors or Certain\nOfficers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**\n\n \n\nOn June 29, 2026, Immunic, Inc., a Delaware\ncorporation (the “Company”) held its annual meeting of stockholders (the “Meeting”). At\nthe Meeting, the Company’s stockholders approved an amendment to the Company’s 2019 Omnibus\nEquity Incentive Plan, as amended (the “Plan”), to increase the number of\nshares of common stock, par value $0.0001 per share (“common stock”), authorized\nfor issuance by 6,000,000 shares to a total of 8,644,887 shares (the “Amendment”).\n\n \n\nA description of the material terms of the\nAmendment is set forth under the heading “Proposal Number 2 —To Approve an Amendment to the Existing 2019 Omnibus Plan”\nin the proxy statement filed with the Securities and Exchange Commission (the “SEC”) on May 29, 2026, which description\nis hereby incorporated into this Item 5.02 by reference. A copy of the Plan, as amended by the Amendment, is attached hereto as Exhibit\n10.1 and is incorporated into this Item 5.02 by reference."}